Tenofovir, an anti-AIDS medicine manufactured by Gilead Sciences was refused patent protection by the Indian patent office. The patent was refused as pre-grant opposition had told authorities that the application did not take any "inventive steps and failed to satisfy the patentability criteria under Indian rules."
Tenofovir happens to be an important drug against AIDS and has been recommended by the WHO as a primary medicine to fight off the virus.
In an unprecedented move Brazilian AIDS advocacy group Brazilian Interdisciplinary AIDS Association (ABIA) joined hands with India's Centre for Residential Care and Rehabilitation (SAHARA) in opposing the patent.
Industry sources say Gilead is likely to appeal against the decision.